## CRL: Charles River Laboratories Inte - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($185.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. What Charles River Laboratories International (CRL)'s SEC Clearance and Analyst Upgrades Mean For Shareholders**
- Source: Simply Wall Street | 20251217T170813 | Somewhat-Bullish | Relevance: 100%
- Charles River Laboratories International (CRL) recently received SEC clearance and analyst upgrades, easing regulatory uncertainty and bolstering confidence in its operations. While this is positive, investors must still consider the near-term challenges of converting backlog to revenue, managing cancellations, and facing pricing pressure from competitors. The company's future also hinges on effectively addressing the growing risk of non-animal testing methods impacting its core revenue.

**2. What Charles River Laboratories International (CRL)'s SEC Clearance and Analyst Upgrades Mean For Shareholders**
- Source: Simply Wall Street | 20251217T010805 | Bullish | Relevance: 100%
- Charles River Laboratories International (CRL) recently received SEC clearance and analyst upgrades, easing regulatory concerns and reinforcing its role in drug development. While these developments reduce regulatory overhang, the company still faces challenges with converting backlog to revenue, managing cancellations, and competitive pricing pressures. Investors should also consider the long-term risk of increasing adoption of non-animal testing methods on CRL's core business.

**3. Should You Continue to Hold CRL Stock in Your Portfolio for Now?**
- Source: TradingView â€” Track All Markets | 20251218T140755 | Neutral | Relevance: 100%
- Charles River Laboratories International (CRL) shows strong prospects in its Research Models and Services segment due to consistent demand and strategic acquisitions, reflected in its solid financial health. However, macroeconomic headwinds and fierce competition pose operational risks. The stock holds a Zacks Rank #3 (Hold), with positive earnings surprises in recent quarters, suggesting potential for continued stability despite market challenges.

**4. Mizuho Adjusts Price Target on Charles River Laboratories International to $200 From $174, Maintains Neutral Rating**
- Source: marketscreener.com | 20251218T135824 | Somewhat-Bullish | Relevance: 100%
- Mizuho has revised its price target for Charles River Laboratories International (NYSE: CRL) to $200, an increase from the previous $174, while retaining a Neutral rating on the stock. This adjustment reflects a change in analyst outlook for the biotechnology and medical research company. The article also highlights recent adjustments from other firms, including Barclays, JPMorgan, and BofA Securities for Charles River Laboratories.

**5. 24 DuPont de Nemours (NYSE:DD) Shares Little Changed in Trade Session**
- Source: Kalkine Media | 20251218T143044 | Neutral | Relevance: 64%
- DuPont de Nemours (NYSE:DD) shares experienced little change during a recent trade session, with the company operating in the basic materials sector. The article provides a detailed look at DuPont de Nemours' segment organization, global operations, and research integration. It also briefly covers why the company is associated with broad market index groupings.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $200 | $174 | +15% |
| 2025-12-15 | Barclays | $215 | $210 | +2% |
| 2025-12-15 | JP Morgan | $190 | $165 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Neutral |
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 18.0x stretched relative to 7% growth. Analyst sentiment positive (3 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.7B |
| Beta | 1.64 |
| 52W Range | $91.86 - $200.58 |
| Short Interest | 6.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 18.0 |
| Current P/E | 19.2 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 7.1% to 1.6% (-5.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.4pp (needs >3.0% for momentum thesis). MRS_5 (-0.7%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.99), confirming momentum. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.60% (CS: 80) | Neutral |
| RSI_14 | 66.3 | Neutral |
| MACD Histogram | 0.99 | Bullish |
| vs SMA20 | 1.061x | Above |
| vs SMA50 | 1.097x | Above |
| vs SMA200 | 1.252x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $197.00
- **Stop Loss:** $185.00 (6.1% risk)
- **Target:** $209.00 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 100
- **Position Value:** $19,700.00
- **Portfolio %:** 19.70%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*